Question 1

Am I eligible for this trial based on my current health and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON) clinical trial (NCT05036005). Contact the study team or your healthcare provider for specific answers.

Question 2

How does Ontruzant compare to other treatments I might consider?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON) clinical trial (NCT05036005). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects of Ontruzant and the chemotherapy involved?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON) clinical trial (NCT05036005). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to visit the clinic during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON) clinical trial (NCT05036005). Contact the study team or your healthcare provider for specific answers.

Question 5

What kind of tests will I need to undergo while participating in this study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON) clinical trial (NCT05036005). Contact the study team or your healthcare provider for specific answers.

Question 6

How will my progress be monitored throughout the treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON) clinical trial (NCT05036005). Contact the study team or your healthcare provider for specific answers.

What this study is about